Home Tags Rituximab

Tag: rituximab

ECHELON-3 Shows investigational Brentuximab Vedotin Regimen Reduced Risk of Death by...

Detailed overall survival (OS) results from the ongoing, randomized, double-blind, multicenter Phase 3 ECHELON-3 study (NCT04404283) investigating brentuximab vedotin (Adcetris®; Pfizer*/Takeda) in combination with...

Polatuzumab Vedotin in the Treatment of Patients with Previously Untreated Diffuse...

Diffuse large B-cell lymphoma (DLBCL), the most common type of an aggressive form of non-Hodgkin lymphoma (NHL) in the United States and worldwide, is...

Polatuzumab Vedotin Shows Complete Response in R/R Diffuse Large B-cell Lymphoma

Polatuzumab vedotin (Polivy™; Genentech/Roche) in combination with bendamustine (Treanda®; Cephalon/Teva Pharmaceutical) and rituximab (Rituxan®; Genentech/Roche) shows encouraging rates of complete response (CR) among patients...

Polatuzumab Vedotin Demonstrates Clinical Efficacy Across a Range of Diffuse Large...

Polatuzumab vedotin (DCDS4501A), a novel, targeted anti-cancer agent being developed by Genentech/Roche, is a first-in-class anti-CD79b antibody-drug conjugate or ADC currently being investigated for...

Polatuzumab Vedotin + Bendamustine and Rituxan Increased Complete Response Rates in...

Positive results from the randomized Phase II GO29365-study (NCT02257567) that compared polatuzumab vedotin (RG7596) in combination with bendamustine plus rituximab (Rituxan®; Genentech/Roche) against bendamustine plus...

Debiopharm Acquires Phase II IMGN529 from ImmunoGen

Debiopharm International, a Swiss biopharmaceutical company, has confirmed that it has acquired ImmunoGen's IMGN529, also known as Debio 1562 or naratuximab emtansine, a clinical-stage anti-CD37 antibody-drug...

AACR 2017: Nine Presentations Feature ImmunoGen’s Approch to ADC development

Earlier today, ImmunoGen, a company at the forefront of antibody-drug conjugates (ADC-) development for the treatment of cancer, announced that nine abstracts highlighting the...

Phase II Clinical Trial of Brentuximab Vedotin Combination Therapy in...

Based on encouraging data in patients with CD30-expressing relapsed or refractory diffuse large B-cell lymphoma or DLBCL, the most common type of aggressive non-Hodgkin Lymphoma...

Polatuzumab Vedotin and Pinatuzumab Vedotin + Rituximab Generally Well-tolerated With Similar...

Updated data on the investigational antibody-drugs conjugates polatuzumab vedotin (anti-CD79b; DCDS4501A) and pinatuzumab vedotin (anti-CD22; DCDT2980S) were presented during the 56th Annual Meeting and...

Study Shows Combination of Epratuzumab and Rituximab in Newly Diagnosed Follicular...

The combination of epratuzumab, a humanized anti CD-22 monoclonal antibody, and rituximab (Rituxan®/Genentech; MabThera®/Roche), as a front-line therapy of patients with newly diagnosed follicular lymphoma (FL), produced...

X